Initial Phase 1b data highlight promising clinical activity in patients with PROC and support continued clinical development of CUSP06At the ...

Vaxcyte Inc. (NASDAQ: PCVX ) stock is surging on Monday on positive topline results from its pivotal Phase 3 OPUS-1 trial ...

VAX-31 beat Pfizer and Merck’s established pneumococcal conjugate vaccines in a Phase 3 trial, exceeding investors’ most ...

Prioritize labels, therapeutics and ADCs; invest in site-specific conjugation, scalable manufacturing and R&D partnerships to capture targeted, personalized therapy demandDublin, Oct. 05, 2026 (GLOBE ...

VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21) Prespecified Co-Primary Immunogenicity Endpoints: In Adults 50 and ...

Summit Therapeutics SMMT is expanding the development of its sole investigational drug, ivonescimab, through a new clinical ...

Hello. I am Taku-sensei, a teacher who teaches Japanese (modern and classical literature) at a private high school and also ...

Jefferies, Leerink Partners, BofA Securities, Goldman Sachs & Co. LLC and Evercore ISI are acting as joint book-running managers for the note offering. Guggenheim Securities and Mizuho are acting as ...

Here are some of the companies making headlines in midday trading. Taiwan Semiconductor Manufacturing , SpaceX – Elon Musk ...

Vaxcyte’s vaccine was pitted against standard-of-care jabs and proved non-inferior on nearly all serotypes.

Coadministration of the MenACYW-TT vaccine with routine pediatric immunizations is well tolerated among healthy infants and ...

Vaxcyte Inc. did even better than expected against competitors in the Opus-1 pivotal phase III trial that tested the safety, ...